Physician profile
Caroline Vickers
NPI 1497127641
$5,982.32
in general payments reported to CMS, 2019-2025
35 companies · $647 in 2025
The $647 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,825 · 2022: $1,495 · 2023: $1,170 · 2024: $845 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,662.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,345.68 | 2021-2025 | |
| Pfizer INC. | $647.69 | 2022-2025 | |
| Glaxosmithkline, LLC. | $435.74 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $429.50 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $370.42 | 2021-2025 | Zepbound, Mounjaro |
| Gilead Sciences, INC. | $340.48 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $325.39 | 2021-2022 | |
| Amgen INC. | $299.07 | 2021-2025 | Repatha, Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company Ltd. | $179.49 | 2022 | |
| Janssen Pharmaceuticals, INC | $156.94 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.12 | 2021-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $135.41 | 2021-2023 | Ajovy |
| Mannkind Corporation | $119.79 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $117.96 | 2021 | |
| Astellas Pharma US INC | $116.92 | 2022-2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $115.93 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $87.27 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.02 | 2021-2024 | Jardiance |
| Upsher-Smith Laboratories LLC | $60.68 | 2021 | |
| Abbott Laboratories | $57.62 | 2021-2024 | Proclaim |
| Hologic Sales and Service, LLC | $50.07 | 2025 | Thinprep 2000 Processor, Aptima |
| Neos Therapeutics, Lp | $46.28 | 2021 | |
| Axsome Therapeutics, INC. | $42.62 | 2022-2025 | Symbravo |
| Adlon Therapeutics L.P. | $39.24 | 2021 | |
| Merck Sharp & Dohme LLC | $36.39 | 2025 | Gardasil 9, Capvaxive |
| Novartis Pharmaceuticals Corporation | $36.06 | 2022-2023 | |
| Lundbeck LLC | $25.35 | 2022 | |
| Genentech USA, INC. | $24.03 | 2021 | |
| Exact Sciences Corporation | $21.84 | 2023 | Cologuard Collection Kit |
| Viiv Healthcare Company | $21.01 | 2023 | Cabenuva |
| Idorsia Pharmaceuticals US INC | $20.17 | 2024 | Quviviq |
| Antares Pharma, INC. | $17.53 | 2024 | Xyosted |
| Jazz Pharmaceuticals INC. | $14.50 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2024 | Livalo |
| Althera Pharmaceuticals LLC | $6.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.